XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Wockhardt has reported total income of Rs. 777 crores during the period ended September 30, 2023
Natco Pharma has reported total income of Rs. 1060.8 crores during the period ended September 30, 2023
Solara Active Pharma Sciences has reported total income of Rs. 426.42 crores during the period ended September 30, 2023
US business grew by +12.8% YoY
Dr. Reddy’s maintains that the allegations against it lack merit and will vigorously defend the litigation
Total transaction value of the divestment is Rs. 3,660 million
PhytoSquene now available for clinical and commercial use
Gland Pharma has reported total income of Rs. 1426.57 crores during the period ended September 30, 2023
Subscribe To Our Newsletter & Stay Updated
